5-Amino-1MQ – Peptide Lexicon

5-Amino-1MQ

5A1MQ · 5-amino-1-methylquinolinium

5-Amino-1MQ, also written 5A1MQ in the literature, is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT). It is a methylquinolinium compound, not a peptide. Research has investigated its effects on adipocyte metabolism and in diet-induced obese mice; these findings do not demonstrate effective weight management or clinical safety in humans.

Published on Sep 30, 2026

Mechanism of action

NNMT transfers a methyl group from S-adenosylmethionine (SAM) to nicotinamide, producing a methylated nicotinamide metabolite. Nicotinamide also participates in NAD metabolism, so this reaction connects with several cellular metabolic pathways. Kraus et al. (2014) investigated NNMT knockdown in mice and adipocyte systems, providing target-level evidence. That work did not test 5-Amino-1MQ. Neelakantan et al. (2018) studied methylquinolinium inhibitors, including this compound, and reported changes in adipocyte metabolites and lipid accumulation. The inhibitors were evaluated in selected permeability and enzyme-selectivity assays. Such testing helps characterize a research tool but does not prove that all off-target effects have been excluded. A target mechanism, a cellular response and a clinical outcome are separate questions.

State of evidence

The specific-compound evidence reviewed here remains preclinical. Neelakantan and colleagues examined 5-Amino-1MQ in high-fat-diet obese mice and reported changes in body weight, adipose tissue and plasma cholesterol. Sampson et al. (2021) studied the compound together with a switch to a lean diet in obese mice. The combined intervention affected body composition and liver-related measures relative to diet substitution alone; the dietary change is an essential part of that result. Babula et al. (2024) investigated a 28-day intervention in diet-induced obese mice, reporting effects on weight and fat-mass gain, glucose handling and liver pathology. These experiments differ in design and cannot be converted into an expected human weight-loss result. The publications include overlapping investigators, and the 2024 paper discloses commercial affiliations. The animal findings justify further research, while human efficacy, durable outcomes and comprehensive safety require their own evidence.

Questions about the research

Is 5-Amino-1MQ a peptide?: No. It is a small methylquinolinium molecule and does not have a peptide amino-acid sequence. It appears here as a related research compound. The distinction matters when comparing substance classes: studies of mitochondrial peptides or other peptide families cannot be attributed to 5-Amino-1MQ simply because they discuss metabolism.
Do the mouse studies show that it causes weight loss in people?: No. They investigate particular animal models under controlled conditions, including defined diets. Mouse changes in body weight or fat mass do not establish a human effect size, effective treatment or long-term safety. The combined diet study also cannot be described as the effect of the compound alone.
Does NNMT inhibition mean all NNMT research applies to this compound?: No. Gene knockdown and different inhibitor molecules are distinct interventions. Their results can inform the target's biology, but only experiments with the identified compound directly characterize 5-Amino-1MQ. The preparation, model, comparator and outcome must all remain visible when assessing a finding; a shared enzyme target does not make substances interchangeable.

Sources

Kraus et al., Nature 2014 (NNMT target knockdown)DOI: 10.1038/nature13198
Neelakantan et al., Biochem Pharmacol 2018DOI: 10.1016/j.bcp.2017.11.007PMID: 29155147
Sampson et al., Sci Rep 2021DOI: 10.1038/s41598-021-85051-6PMID: 33707534
Babula et al., Diabetes Obes Metab 2024DOI: 10.1111/dom.15879PMID: 39161060

5-Amino-1MQ

5A1MQ · 5-amino-1-methylquinolinium

Published on Sep 30, 2026

Mechanism of action

State of evidence

Questions about the research

Is 5-Amino-1MQ a peptide?

No. It is a small methylquinolinium molecule and does not have a peptide amino-acid sequence. It appears here as a related research compound. The distinction matters when comparing substance classes: studies of mitochondrial peptides or other peptide families cannot be attributed to 5-Amino-1MQ simply because they discuss metabolism.

Do the mouse studies show that it causes weight loss in people?

No. They investigate particular animal models under controlled conditions, including defined diets. Mouse changes in body weight or fat mass do not establish a human effect size, effective treatment or long-term safety. The combined diet study also cannot be described as the effect of the compound alone.

Does NNMT inhibition mean all NNMT research applies to this compound?

No. Gene knockdown and different inhibitor molecules are distinct interventions. Their results can inform the target's biology, but only experiments with the identified compound directly characterize 5-Amino-1MQ. The preparation, model, comparator and outcome must all remain visible when assessing a finding; a shared enzyme target does not make substances interchangeable.